Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Virus Diseases Clear all
Completed Phase 1 Interventional

BMS-247550 in Treating Patients With Advanced Cancers

NCT00006221
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 26, 2026, 4:17 PM EDT
Terminated Phase 1 Interventional Results available

Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

NCT02919449
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Cancer
Interventions
MV-NIS, Atezolizumab
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 4 Interventional

A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions

NCT00144248
View directory record Official record
Conditions
HIV Infections, Hepatic Insufficiency
Interventions
nevirapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
5
States / cities
Bakersfield, California • San Francisco, California • Albany, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 26, 2026, 4:17 PM EDT
Active, not recruiting No phase listed Observational

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

NCT05615415
View directory record Official record
Conditions
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
Interventions
PET Tracer, MRI Tracer, 3T PET/MRI
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 2 Interventional

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

NCT00002235
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
13 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC

NCT00000999
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 26, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

NCT06971614
View directory record Official record
Conditions
Nonmuscle-invasive Bladder Cancer
Interventions
T3011
Biological
Lead sponsor
ImmVira Pharma Co. Ltd
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Queen Creek, Arizona • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

NCT00623649
View directory record Official record
Conditions
HCV Infection
Interventions
VCH 916, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception

NCT01667978
View directory record Official record
Conditions
Pregnancy, HIV, AIDS
Interventions
Norethindrone acetate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Evaluation of Tailored Messages to Address Parental Questions About HPV Vaccination

NCT03628885
View directory record Official record
Conditions
Human Papilloma Virus Vaccines, Attitude to Health
Interventions
Top Concern Tailored Intervention, All Concerns Tailored Intervention
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
908 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Exclusion Criteria in a University Population

NCT01472536
View directory record Official record
Conditions
Influenza
Interventions
Sequestration
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance

NCT01210404
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
filibuvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

NCT00654147
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir & Lopinavir/ritonavir, Raltegravir and emtricitabine/tenofovir
Drug
Lead sponsor
Margaret A. Fischl, M.D.
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients

NCT00002363
View directory record Official record
Conditions
HIV Infections
Interventions
Peptide Construction 3, Synthetic
Drug
Lead sponsor
Columbia Research Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional

Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy

NCT04542993
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Zinc Picolinate, Resveratrol, Zinc Picolinate Placebo, Resveratrol Placebo
Dietary Supplement
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

NCT00516321
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 26, 2026, 4:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

NCT07065747
View directory record Official record
Conditions
Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 26, 2026, 4:17 PM EDT
Not listed Phase 1 Interventional

Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy

NCT00002449
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
23
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 4:17 PM EDT
Terminated Early Phase 1 Interventional Results available

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

NCT02827838
View directory record Official record
Conditions
Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Biological · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

NCT01492426
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Telaprevir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 2 Interventional

Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

NCT00000626
View directory record Official record
Conditions
HIV Infections, Hodgkin's Disease
Interventions
Vinblastine sulfate, Dacarbazine, Filgrastim, Bleomycin sulfate, Doxorubicin hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Treatment Cascade Optimization Study

NCT05305443
View directory record Official record
Conditions
COVID-19
Interventions
Navigation Services, Brief Counseling, Critical Dialogue, Referral and Digital Brochure
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Saint Louis, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Not applicable Interventional

Directly Observed Hepatitis C Treatment in Methadone Clinics

NCT01442311
View directory record Official record
Conditions
Hepatitis C, Medication Adherence
Interventions
enhanced DOT (both pegylated interferon alfa-2a and ribavirin), standard DOT (PEG-DOT control arm)
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 26, 2026, 4:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects

NCT00848211
View directory record Official record
Conditions
HIV Infections
Interventions
Placebo, TUTI-16 (0.03mg), TUTI-16 (0.1mg), TUTI-16 (0.6mg)
Other · Biological
Lead sponsor
Thymon, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Sep 26, 2026, 4:17 PM EDT